araag2/HINT huggingface dataset:
Clinical trial NCT00151632 (phase 3, status: terminated)
Conditions: evidence of liver transplantation
ICD codes: Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, K70.0
Drugs: mycophenolate mofetil, tacrolimus
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O
Reason stopped: 
    insufficient enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Adults over 18 years of age

          -  Primary liver transplantation

          -  Immunosuppressive treatment associating tacrolimus and steroids at low doses (< 20
             mg/d)

          -  Written informed consent

        Non-Inclusion Criteria:

          -  Pregnancy or ineffective contraception

          -  Immunosuppressive treatment

          -  Blood group incompatibility with the donor

          -  Autoimmune hepatitis

          -  Fulminant hepatitis

          -  Primary sclerosing cholangitis

          -  Combined transplantations

          -  Reduced liver

          -  Living donor

          -  Treated hypertension and/or diastolic pressure ≥ 90 mmHg and/or systolic pressure ≥
             140 mmHg,

          -  Acute or chronic renal failure(creatininemia ≥ 130 μmol/L) before transplantation

          -  Treated diabetes and/or fasting glycemia ≥ 7 mmol/L

          -  Treated hypercholesterolemia and/or cholesterolemia ≥ 7 mmol/L

          -  post-operative creatininemia ≥ 200 μmol/L
Clinical trial NCT00250562 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: valsartan plus hydrochlorothiazide
SMILES: CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  - Male or female Outpatients 18 years and older.

          -  Patients with hypertension defined as the following:

          -  Newly diagnosed hypertensive patients should have a MSDBP > 95 mmHg and < 110 mmHg.at
             Visit 1 and 2, Pre-treated hypertensive patients should have a MSDBP > 95 mmHg and <
             110 mmHg at Visit 2

          -  For entrance into the double-blind treatment period (Visit 3), all patients should
             have a MSDBP of > 90 mmHg and < 110 mmHg

          -  Patients must have given written informed consent to participate and be willing to
             participate in the entire study

        Exclusion Criteria:

        -
Clinical trial NCT00088010 (phase 3, status: completed)
Conditions: osteoporosis, postmenopausal
ICD codes: N95.0, N95.2
Drugs: arzoxifene, placebo
SMILES: COC1=CC=C(C=C1)C1=C(OC2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  60-85 years of age

          -  Female

          -  At least two years since last menstrual cycle

        Exclusion Criteria:

          -  Abnormal or unexplained vaginal bleeding.

          -  Bone disorders, other than osteoporosis or low bone mass

          -  History of breast cancer, cancer of the uterus, or any cancer in the last five years
             (except skin cancer).

          -  History of cerebral vascular accidents or venous thromboembolic events

          -  Medications outlined
Clinical trial NCT01135550 (phase 3, status: terminated)
Conditions: vomiting, headache
ICD codes: R11.10, R11.12, R11.14, R11.11, K91.0, O21.2, O21.8, G44.81, G44.86, R51.9, G44.53, G44.83, G44.84, G44.85
Drugs: high dose dexamethasone, low dose dexamethasone
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Reason stopped: 
    premature closure due to lack of accrual
  
Eligibility criteria:

        Inclusion Criteria for Enrolment:

          -  Children between 2-18 years of age.

          -  Children who underwent resection of a brain tumour with ≤ 1.5 cm2 residual tumour
             after surgical resection.

          -  Children regardless of extent of leptomeningeal or spinal metastasis (M1-3) are
             eligible.

          -  Children who undergo focal or whole brain (± spinal) radiation as part of their brain
             tumour treatment.

          -  Children treated at one of the 16 tertiary care centers in Canada (CPBTC).

          -  Patients on any anticonvulsive treatment are eligible.

          -  Patients on concomitant chemotherapy while undergoing radiation are eligible.

          -  Patients must be ≥ 24 hours steroid-free prior to starting radiation.

          -  Parents/legal guardians have to have signed and dated an informed consent to allow
             study enrolment of their child. (As per institutional guidelines, patients over a
             certain age may have signed their own informed consent form.)

          -  Patients > 8 years of age should assent to study participation.

          -  Patients less than 10 years of age should have a Lansky Score of >/= 50.

          -  Patients 10 years of age or older should have a Karnofsky Score of >/= 50. If ECOG
             performance scale is used, patient should have a score of 0, 1 or 2.

        Exclusion Criteria for Enrolment:

          -  Children with residual brain tumour lesion > 1.5 cm2 after surgical resection.

          -  Children on steroids (dexamethasone) that will not be stopped ≥ 24 hours prior to
             start of radiation therapy.

        Inclusion Criteria for Randomization to a Dexamethasone treatment group:

          -  Patients must have been enrolled on the Dexamethasone study prior to the start of
             radiation therapy.

          -  Children who develop either symptoms of vomiting (defined as either retching or
             vomiting ≥ once per day) or headache (≥ 2 points increase in severity of the most
             intense headache/day) while undergoing irradiation.

          -  Patients who are currently undergoing focal or whole brain (± spinal) radiation.

        Exclusion Criteria for Randomization to a Dexamethasone treatment group:

          -  Patients who were not enrolled on Dexamethasone study prior to start of radiation
             therapy.
Clinical trial NCT00644969 (phase 3, status: completed)
Conditions: smoking cessation
ICD codes: Y36.881S, Y36.891S, Y36.880S, Y36.881A, Y36.881D, Y36.890S, Y36.891A
Drugs: placebo, varenicline (cp-526,555)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@]12C[C@]([H])(CNC1)C1=CC3=NC=CN=C3C=C21
Eligibility criteria:

        Inclusion Criteria:

          -  Have a diagnosis (using the SCID-I/P at screening visit) of schizophrenia or
             schizoaffective disorder and judged to be stable (without hospitalization or acute
             exacerbation and functioning in society) on psychiatric treatment for at least the
             past 6 month.

          -  Current cigarette smokers (at least 15/day during the past year with no period of
             abstinence greater than 3 months in the past year) male or female, between the ages of
             18 and 75 inclusive, who are motivated to stop smoking.

          -  Score 7 or higher on the Contemplation Ladder at the Screening, Week -1, and Baseline
             Visits.

        Exclusion Criteria:

          -  PANSS score >70 at Screen or Baseline Visit.

          -  Subjects hospitalized within the past six months due to suicidal ideation or suicidal
             behavior or subjects considered to have serious suicidal ideation or suicidal behavior
             within the past six moth.

          -  Subjects having active suicidal ideation or behavior identified at Screen, Week -1, or
             Baseline Visit.

          -  Subjects taking Bupropion.
Clinical trial NCT00171691 (phase 3, status: completed)
Conditions: osteoarthritis
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: diclofenac topical sodium gel 1%
SMILES: OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
Eligibility criteria:

        Key Inclusion criteria

        • Osteoarthritis of the knee

        Key Exclusion criteria

          -  Other rheumatic disease, such as rheumatoid arthritis

          -  Active gastrointestinal ulcer during the last year

          -  Known allergy to analgesic drugs
Clinical trial NCT01199783 (phase 3, status: terminated)
Conditions: diabetic foot
ICD codes: Z86.31
Drugs: daptomycin, vancomycin
SMILES: CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=C(N)C=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O, CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=C(N)C=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O
Reason stopped: 
    patient number to be enrolled not reachable in prospected time frame, decision to stop the
    study prematurely was made.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Type 1 and Type 2 Diabetes mellitus

          -  MRSA infected foot ulcus Wagner 1-2 without primary surgical intervention

          -  Therapy duration will last at least more than 5 days

          -  men and women age 18 - 80 years

          -  Declaration of patient's consent

          -  Ability and willingness to give written informed consent and to comply with the
             requirements of the study

          -  Sexually active females, unless surgically sterile, must be willing to use 2 forms of
             contraception through the end of the study. Sexually active woman must, except if they
             were surgically sterilized, have to use for already 30 days before first dose of study
             medication an effective method of pregnancy prevention. Acceptable forms of
             contraception for female subjects include: oral, transdermal, injectable or implanted
             contraceptives, intrauterine device (IUD), female condom, diaphragm with spermicide,
             cervical cap, absolute waiver of sexual intercourse, use of a condom by the sexual
             partner, or sterile sexual partner. Male subjects with partners of child-bearing
             potential should use barrier contraception in addition to having their partners use
             another method of contraception.

        Exclusion Criteria:

          -  Osteomyelitis according to international consensus guideline (3 of 5 criteria apply
             for diagnosis)

          -  Presence of a severe nephropathy (creatinine clearance < 30 ml/min)

          -  Advanced diabetic retinopathy

          -  Simultaneous participation in another study or participation in a study in the past 30
             days

          -  Non permissible concomitant medication e.g. therapy regimen using several antibiotics

          -  Contraindication for antibiotics

          -  Dialysis essential

          -  Pregnancy (to be determined by pregnancy test) or unsafe contraception

          -  Neutropenia

          -  immunosuppression (oral immunosuppressives, Corticoids exaggerating 7.5 mg
             Prednisolon-equivalents)

          -  Chronic liver disease (AST or ALT increased to 10fold, bilirubin increased to
             threefold compared to normal values)
Clinical trial NCT00375895 (phase 3, status: terminated)
Conditions: chronic hepatitis c, evidence of liver transplantation
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4, Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, K70.0
Drugs: ciclosporin
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
Reason stopped: 
    insufficient enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Adults aged 18 or over,

          -  Who had been included in the Transpeg 1 study,

          -  Non-responders after a three month peginterferon alfa-2a / ribavirin bitherapy or with
             a recurrent disease during the Transpeg 1 maintenance phase, whatever the
             randomization group (ribavirin or placebo),

          -  With a positive qualitative PCR at inclusion,

          -  With a METAVIR histologic score of 1 or more on the last biopsy (done within the 6
             months preceding inclusion),

          -  Treated with tacrolimus for at least 6 months prior to inclusion,

          -  Having given a written informed consent.

        Exclusion Criteria:

          -  Treatment with peginterferon or ribavirin within the 6 months preceding inclusion,

          -  Severe hepatocellular failure or decompensated cirrhosis,

          -  Acute graft rejection within the two months preceding inclusion, or signs of chronic
             rejection on the last biopsy, or retransplantation since inclusion in the Transpeg 1
             study,

          -  Treatment with cyclosporin for more than 6 months during the 24 months preceding
             inclusion,

          -  Treatment with a mTOR inhibitor or with another investigational immunosuppressive
             drug,

          -  Positive serology for HIV or HBV,

          -  Cancer (or history of other malignancy during the last 5 years) except patients
             transplanted for hepatocellular carcinoma and basocellular or excised spinocellular
             carcinoma,

          -  Serious concomitant disease or acute or chronic disorder, other than the current
             transplant, treated with steroids,

          -  Serious cardiac pathology within the last 6 months,

          -  Women with ongoing pregnancy or breast-feeding,

          -  Serious chronic renal failure (creatinine clearance < 30 ml/mn),

          -  Haemoglobin < 10 g/dl, platelets < 50 000/mm3 or neutrophils < 1000 / mm3,

          -  Abnormal TSH values,

          -  Inability to cooperate or to communicate with the investigator,

          -  Contraindications to ribavirin, peginterferon alfa-2a or cyclosporin.
Clinical trial NCT00032084 (phase 3, status: terminated)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: bupropion hydrochloride, nicotine
SMILES: CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1, CC(=O)NC1=CC=C(O)C=C1
Reason stopped: 
    this study was closed early due to poor accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of stage I or II non-small cell lung cancer with complete resection of all
             disease

               -  Must be free of recurrent or progressive disease

          -  Current smoker defined as:

               -  Smoked at least 100 cigarettes in entire life AND

               -  Currently smoking some days or every day

          -  Must establish a quit date that falls within 30 days after registration, but 7 days
             after physician advice and start of bupropion or placebo therapy

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Zubrod 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Cardiovascular:

          -  Not within an immediate post-infarction period

          -  No uncontrolled arrhythmias

          -  No unstable angina

          -  No uncontrolled hypertension (unstable blood pressure, diastolic pressure 90 mm Hg or
             greater)

        Other:

          -  Must be able to read, speak, and understand English

          -  Must be willing to allow testing of saliva for cotinine levels

          -  No history of seizures

          -  No history of eating disorders

          -  No known drug-drug interactions between nicotine patch and/or bupropion and patient's
             current or planned medications including chemotherapy and antiemetics

          -  No concurrent psychiatric diagnosis that would preclude study compliance

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Concurrent adjuvant chemotherapy allowed

        Endocrine therapy:

          -  No concurrent systemic steroids

        Radiotherapy:

          -  Concurrent adjuvant radiotherapy allowed

        Surgery:

          -  See Disease Characteristics

          -  Recovered from prior surgery

        Other:

          -  Prior neoadjuvant therapy allowed

          -  At least 14 days since prior medications containing bupropion (e.g., Wellbutrin or
             Wellbutrin SR)

          -  No other concurrent medications that contain bupropion (e.g., Wellbutrin or Wellbutrin
             SR)

          -  No concurrent monoamine oxidase inhibitors

          -  No concurrent medications that lower seizure threshold (e.g., antipsychotics,
             antidepressants, or theophylline)

          -  No other concurrent nicotine replacement therapy
Clinical trial NCT00180089 (phase 3, status: completed)
Conditions: leukemia, graft-versus-host disease
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, D89.810, D89.811, D89.813, D89.812
Drugs: budesonide
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  planned allogenic stem cell or bone marrow transplantation

          -  HLA identity (max. 1 mismatch)

          -  standard GVHD prophylaxis with cyclosporin A or tacrolimus combined with MTX, +/- ATG
             or Campath1H

          -  written informed consent

        Exclusion Criteria:

          -  history of allogenic transplantation

          -  in vitro T-cell depleted transplant

          -  pretreatment with budesonide within the previous 4 weeks

          -  known intolerance to budesonide

          -  gastrointestinal infections

          -  portal hypertension

          -  concomitant infectious diseases

          -  liver cirrhosis, impaired liver function

          -  severe mental disorder

          -  lack of compliance

          -  drug or alcohol abuse

          -  pregnancy, lactation

          -  childbearing potential without effective contraception
Clinical trial NCT01736150 (phase 3, status: completed)
Conditions: chronic kidney disease, chronic kidney disease on hemodialysis
ICD codes: I12.9, N18.9, I12.0, D63.1, N18.1, N18.5, I13.0
Drugs: placebo, sevelamer carbonate
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NCC=C.ClCC1CO1
Eligibility criteria:

        Inclusion Criteria:

          -  On hemodialysis regimen scheduled for four hour duration three times per week for a
             minimum 30 days prior to Visit 1 and throughout the study

          -  Have a central laboratory serum iPTH measurement less than 1000 pg/mL at Visit 1

          -  Have a central laboratory serum phosphorus measurement greater than 5.5 mg/dL at Visit
             1a

        Exclusion Criteria:

          -  Active dysphagia or swallowing disorder; or a predisposition to or current bowel
             obstruction, ileus, or severe gastrointestinal (GI) motility disorders including
             severe constipation

          -  Documented poorly controlled diabetes mellitus, poorly controlled hypertension, active
             vasculitis, human immunodeficiency virus infection, or any clinically significant
             unstable medical condition
Clinical trial NCT00174837 (phase 3, status: completed)
Conditions: head and neck squamous cell carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: tirapazamine, cisplatin
SMILES: NC1=[N+]([O-])C2=C(C=CC=C2)[N+]([O-])=N1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Previously untreated squamous cell carcinoma of the oral cavity, oropharynx,
             hypopharynx, or larynx.

          -  Stage III or IV disease (excluding T1N1, and T2N1 and metastatic disease).

          -  Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.

          -  Absolute neutrophil count at least 1.5 X 10^9/L, platelet count at least 100 X 10^9/L,
             and hemoglobin > 9g/dL.

          -  Serum bilirubin < 1.25 times upper limit of normal (ULN) and aspartate
             aminotransferase (AST)/alanine transaminase (ALT) < 2.5 times ULN.

          -  Calculated creatinine clearance (Cockcroft-Gault) > 55 mL/min.

        Exclusion Criteria:

          -  Metastatic Disease

          -  Primary cancers of the nasal and paranasal cavities and of the nasopharynx

          -  Significant intercurrent illness that will interfere with the Chemotherapy or
             Radiation Therapy during the trial

          -  Symptomatic peripheral neuropathy > grade 2

          -  Clinically significant hearing impairment

          -  Significant cardiac disease
Clinical trial NCT00094926 (phase 3, status: completed)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: risperdal consta, placebo
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Must provide informed consent

          -  Must agree to receive regular injections

          -  Must have current diagnosis of bipolar disorder I or II

          -  Must have at least four episodes of mood disorder in the last year that required
             psychiatric intervention

        Exclusion Criteria:

          -  Female who is or may be pregnant or breastfeeding, who is not at least 1 year
             postmenopausal, or is not using reliable and adequate birth control

          -  Psychiatric diagnosis is due directly to effects of a substance or general medical
             condition

          -  Substance dependence

          -  Received treatment with a long-acting injectable antipsychotic less than 2 injection
             cycles prior to baseline (so, for example, if the drug is injected every 2 weeks, the
             patient could not enroll in the study if they had received an injection within the
             last 4 weeks)

          -  Received Electroconvulsive Therapy (ECT) within the last month

          -  Began psychotherapy ("talk therapy") within 2 months

          -  In the past month was treated with any of these medications: carbamazepine,
             oxcarbazepine, fluoxetine, paroxetine, or clozapine